# Oculeve

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oculeve

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.oculeve.com
- Total disclosed funding: $24M
- Latest round: Series B (Mar 18, 2014)
- Investors on record: 3

## About

Oculeve, Inc. specializes in developing innovative therapies for dry eye conditions using its proprietary technology to provide effective and targeted treatments for patients.Founded in 2011, Oculeve, Inc. focuses on advanced therapeutic solutions for ocular health. The company was acquired by Allergan Inc in July 2015 for USD 125 mn. It is located in South San Francisco, US. The founder of Oculeve is not specified in the provided data.Following its acquisition by Allergan, Oculeve's technologies are integrated within a diverse portfolio that addresses eye care needs, particularly for dry eye conditions. The company contributes to Allergan's extensive offerings, which include over 30 brands targeting more than 60 medical conditions across various therapeutic areas, including eye care.Oculeve generates revenue through Allergan's established channels, leveraging direct-to-consumer sales and B2B partnerships with healthcare providers. Revenue is supported by Allergan's recognized products in the eye care segment, maintaining competitive pricing strategies in the pharmaceutical industry.Post-acquisition, Oculeve's future growth is aligned with Allergan's strategic initiatives, which include launching new eye care products and expanding into new geographic markets. The acquisition deal in July 2015 will allow Allergan to utilize the USD 125 mn investment to enhance R&D efforts in developing innovative therapies for ocular health.

## Funding rounds

- Series B, Mar 18, 2014, $17M — Kleiner Perkins, New Enterprise Associates, Versant Ventures
- Series A, Oct 30, 2012, $7.6M — Kleiner Perkins, New Enterprise Associates, Versant Ventures

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B